Cargando…

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: During the last decades, scientific advances in immuno-oncology and a better understanding of tumors’ immune profile led to the development of novel immunotherapeutic strategies, especially immune checkpoint inhibitors. The blockade of PD-1 by monoclonal antibodies (mAbs) is the only...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veigas, Florencia, Mahmoud, Yamil D., Merlo, Joaquin, Rinflerch, Adriana, Rabinovich, Gabriel Adrian, Girotti, María Romina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957692/ https://www.ncbi.nlm.nih.gov/pubmed/33804419 http://dx.doi.org/10.3390/cancers13051018

Ejemplares similares

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
por: Segovia, Mercedes, et al.
Publicado: (2019)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
por: Lechner, Axel, et al.
Publicado: (2017)

Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers
por: Suzuki, Susumu, et al.
Publicado: (2020)

Identification of immune‐related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma
por: Li, Qun, et al.
Publicado: (2022)

Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
por: Girotti, María Romina, et al.
Publicado: (2019)

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
por: Poulose, Jissy Vijo, et al.
Publicado: (2022)

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
por: Dong, Hui, et al.
Publicado: (2023)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
por: Wang, Hui-Ching, et al.
Publicado: (2020)

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Economopoulou, Panagiota, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Sakai, Akihiro, et al.
Publicado: (2023)

Profiles of immune cell infiltration in head and neck squamous carcinoma
por: Liang, Bin, et al.
Publicado: (2020)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
por: von der Grün, Jens, et al.
Publicado: (2019)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
por: Lee, Yun-Gyoo, et al.
Publicado: (2021)

Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
por: Gavrielatou, Niki, et al.
Publicado: (2023)

Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy
por: Rühle, Alexander, et al.
Publicado: (2022)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites
por: Wondergem, Niels E., et al.
Publicado: (2020)

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Wang, Hui-Ching, et al.
Publicado: (2019)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021)

Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
por: Elmusrati, Areeg, et al.
Publicado: (2021)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
por: Jia, Yi-Qun, et al.
Publicado: (2019)

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023)

Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck
por: Santos-de-Frutos, Karla, et al.
Publicado: (2019)

Roles of the Wnt Signaling Pathway in Head and Neck Squamous Cell Carcinoma
por: Xie, Jing, et al.
Publicado: (2021)

Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
por: Kordbacheh, Farzaneh, et al.
Publicado: (2021)

The Role of Hedgehog Signaling Pathway in Head and Neck Squamous Cell Carcinoma
por: Cierpikowski, Piotr, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_caupl423hkmvbuh6camabp23n3